STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACAD
  4. [Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

ACADIA (NASDAQ: ACAD) awards options and RSUs to Chief Commercial Officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS EVP and Chief Commercial Officer Thomas Garner reported compensation-related equity awards. He received stock options for 97,947 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty-five percent of these options vest on March 6, 2027, with the rest vesting in 36 equal monthly installments. He was also granted 28,493 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are awards from the company, not open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Garner Thomas
Role EVP, Chief Commercial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 97,947 $0.00 --
Grant/Award Restricted Stock Units 28,493 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 97,947 shares (Direct); Restricted Stock Units — 28,493 shares (Direct)
Footnotes (1)
  1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vest in four equal annual installments beginning March 6, 2027.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garner Thomas
(Last) (First) (Middle)
C/O ACADIA PHARMACEUTICALS, INC.
12830 EL CAMINO REAL, SUITE 400
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $22.16 03/06/2026 A 97,947 (1) 03/05/2036 Common Stock 97,947 $0 97,947 D
Restricted Stock Units (2) 03/06/2026 A 28,493 (3) (3) Common Stock 28,493 $0 28,493 D
Explanation of Responses:
1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.
/s/ Jennifer J. Rhodes, Attorney-in-Fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did ACAD (ACADIA PHARMACEUTICALS) grant to Thomas Garner?

ACAD granted Thomas Garner stock options for 97,947 shares at $22.16 per share and 28,493 restricted stock units. Both awards are structured to vest over several years, aligning his compensation with longer-term company performance.

Are Thomas Garner’s Form 4 transactions in ACAD stock open-market buys or sells?

The Form 4 shows grants, not open-market trades. Garner received stock options and restricted stock units as compensation awards from ACAD, so no shares were bought or sold in the market in these reported transactions.

How do Thomas Garner’s ACAD stock options vest over time?

Twenty-five percent of the 97,947 stock options vest on March 6, 2027. The remaining 75% vest in 36 equal monthly installments thereafter, creating a multi-year vesting schedule tied to his continued service with the company.

What is the vesting schedule for Thomas Garner’s ACAD restricted stock units?

The 28,493 restricted stock units vest in four equal annual installments beginning March 6, 2027. Each vested unit entitles Garner to receive one share of ACADIA’s common stock, providing gradually realized equity compensation over four years.

What does each restricted stock unit represent in the ACAD grant to Thomas Garner?

Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Shares are delivered as units vest over time, meaning Garner gains actual stock only when vesting conditions are satisfied.

What is the exercise price and expiration date of Thomas Garner’s ACAD stock options?

Garner’s stock options have an exercise price of $22.16 per share and expire on March 5, 2036. He can exercise vested options any time before expiration, subject to company policies and any applicable trading restrictions.